The COOH Terminus of GATE-16, an Intra-Golgi Transport Modulator, Is Cleaved by the Human Cysteine Protease HsApg4A*

Ruth Scherz-Shouval, Yuval Sagiv, Hagai Shorer, and Zvulun ElazarDagger

From the Department of Biological Chemistry, The Weizmann Institute of Science, Rehovot 76100, Israel

Received for publication, November 27, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Docking of a vesicle at the appropriate target membrane involves an interaction between integral membrane proteins located on the vesicle (v-SNAREs) and those located on the target membrane (t-SNAREs). GATE-16 (Golgi-associated ATPase enhancer of 16 kDa) was shown to modulate the activity of SNAREs in the Golgi apparatus and is therefore an essential component of intra-Golgi transport and post-mitotic Golgi re-assembly. GATE-16 contains a ubiquitin fold subdomain, which is terminated at the carboxyl end by an additional amino acid after a conserved glycine residue. In the present study we tested whether the COOH terminus of GATE-16 undergoes post-translational cleavage by a protease which exposes the glycine 116 residue. We describe the isolation and characterization of HsApg4A as a human protease of GATE-16. We show that GATE-16 undergoes COOH-terminal cleavage both in vivo and in vitro, only when the conserved glycine 116 is present. We then utilize an in vitro assay to show that pure HsApg4A is sufficient to cleave GATE-16. The characterization of this protease may give new insights into the mechanism of action of GATE-16 and its other family members.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Vesicular transport of proteins is mediated by coated vesicles that bud from membrane-bound compartments and fuse with a target acceptor organelle. This process is highly conserved from yeast to man. Docking of a vesicle at the appropriate target membrane involves an interaction between integral membrane proteins located on the vesicle, the v-SNAREs,1 and the t-SNAREs at the target membrane (1-3). After fusion of the membranes, the tightly bound v-t-SNARE complex binds two soluble factors: N-ethylmaleimide-sensitive fusion protein (NSF) and soluble NSF attachment protein (SNAP). NSF catalyzes SNARE complex disassembly via its ATPase activity, thus allowing a new round of fusion to take place (4-6).

GATE-16 (Golgi-associated ATPase enhancer of 16 kDa) is an essential component of intra-Golgi transport (7) and post-mitotic Golgi re-assembly (8). GATE-16 is recruited to unpaired GOS-28, a Golgi-specific SNARE, in an NSF/alpha -SNAP-dependent manner (7, 8), thus preventing GOS-28 from interacting with its cognate t-SNARE syntaxin 5. As was determined by its crystal structure (9), GATE-16 contains a ubiquitin fold decorated by two additional NH2-terminal helices. GATE-16 belongs to the ubiquitin-like protein family and shares a high level of sequence identity with an expanding family of proteins that have been implicated in a variety of cellular processes. Members of this family include light chain 3, a subunit of the neuronal microtubule-associated protein complex (10) recently implicated in autophagocytosis (11, 12) and the GABA receptor-associated protein (GABARAP), which was implicated in GABAA receptor trafficking and post-synaptic localization (13-15). In Saccharomyces cerevisiae there is only one known homologue of GATE-16, Aut7/Apg8, which was found to function in membrane dynamics during autophagy (16, 17). This process constitutes a major pathway for delivery of proteins and organelles to the lysosome or vacuole, where they are degraded and recycled. Autophagy is particularly important during development as well as under certain environmental stress conditions such as nitrogen starvation. Aut7p is essential for autophagosome biogenesis, playing a key role in the formation (12) and elongation of autophagosomes (18). Despite its hydrophilic nature, considerable amounts of Aut7p are covalently bound to membranes, specifically conjugated to phosphatidylethanolamine (PE) (19, 20). For this conjugation to occur, Aut7p must undergo a series of modifications. First, newly synthesized Aut7p is cleaved downstream of glycine 116 (out of 117 AA) by Apg4p/Aut2p, a cytosolic cysteine protease. Next, Aut7p becomes conjugated to PE through the exposed COOH-terminal glycine by a ubiquitination-like mechanism, involving Apg7p as an E1-like enzyme and Apg3p as an E2-like enzyme (20). Finally, conjugated Aut7p is cleaved again by Apg4p downstream of glycine 116 and thereby released from the membrane (19).

We have previously found that GATE-16 isolated from bovine brain lacks its phenylalanine residue at position 117 (7). We now describe the isolation and characterization of HsApg4A as a human protease of GATE-16. We show that GATE-16 is cleaved downstream of a conserved and essential glycine 116, both in vivo and in vitro. We then utilize a cell-free assay to show that HsApg4A is sufficient to cleave GATE-16. These findings, together with the identification of the human Apg7 (21) and Apg3 (22), indicate that GATE-16 undergoes a similar modification to that of its yeast homologue, Aut7. The isolation of HsApg4A provides a new tool for further investigation and characterization of the role of GATE-16 in intracellular membrane trafficking.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cloning of the Human Apg4 Homologue-- Based on the DNA sequence of HsApg4A (GenBankTM accession number AB066214), we cloned an open reading frame of the HsApg4A cDNA by PCR, using an expressed sequence tag clone (number 309651 from ResGen, Invitrogen) as a template. This cDNA fragment was sequenced and found to correspond to the authentic HsApg4A sequence. The fragment was then subcloned into a pQE-30 expression vector (Qiagen), and the obtained construct was designated pQE-30HsApg4A. This construct encodes a recombinant protein tagged by His6 at the NH2 terminus.

Plasmid Construction and Site-directed Mutagenesis of GATE-16-- The open reading frame encoding GATE-16 was amplified by PCR and subcloned into a pcDNA3 plasmid (Invitrogen), upstream to a sequence encoding for a hemagglutinin (HA) tag, to produce a protein tagged by HA at the COOH terminus. This construct, designated pcDNA3GATE-16-HA, was used for the in vivo studies. Two mutant genes were constructed based on the WT construct: G116A, in which glycine 116 was replaced with alanine, and F115A, in which phenylalanine 115 was replaced with alanine. Mutagenesis was carried out by the Pfu DNA polymerase (New England BioLabs) with an oligonucleotide containing 5'-TTCGCCTTC-3' and 5'-GCCGGCTTC-3', respectively (the nucleotides that were changed to generate the mutations are underlined).

To express GATE-16-HA as a recombinant protein, the cDNA encoding GATE-16-HA was amplified by PCR from pcDNA3GATE-16-HA and subcloned into a pQE-30 bacterial expression vector (Qiagen). This construct encodes a recombinant protein tagged by His6 at the NH2 terminus and HA at the COOH terminus. Similarly, pQE-30 vectors containing the mutants G116A and F115A were constructed.

Expression and Purification of Recombinant Proteins-- The pQE-30 plasmid containing GATE-16-HA was transformed into the Escherichia coli M15 (pREP4) strain. Cells were grown to an OD600 of 0.3-0.6 and induced with 1 mM isopropyl-l-thio-beta -D-galactopyranosidase for 3-4 h at 37 °C. Following centrifugation in a Sorvall SLA-3000 rotor at 6000 rpm for 15 min, the pellet was resuspended in a breaking buffer (10 mM Hepes, pH 7.4, 200 mM KCl, 10 mM beta -mercaptoethanol, 1 mM phenylmethylsulfonyl fluoride (PMSF), 2 µg/ml leupeptin, 2 µg/ml aprotonin, and 2 µM pepstatin A) and lysed by high pressure (8000 p.s.i.). The lysates were cleared by 30-min centrifugation at 40,000 rpm in a Beckman Ti60 rotor and then loaded onto a nickel beads column (nickel-nitrilotriacetic acid (Ni2+-NTA), Qiagen). The column was washed with washing buffer (10 mM Hepes, pH 7.4, 50 mM KCl, 10 mM beta -mercaptoethanol) containing 20 mM imidazole, and elution was carried out in a gradient of 20-500 mM imidazole in the same buffer. Samples were detected on SDS-PAGE, and the protein concentration was determined by the Bradford assay (Bio-Rad). Fractions containing pure GATE-16-HA were stored at -70 °C until use. A similar method was used for the purification of recombinant His6-HsApg4A from pQE-30HsApg4A, except for the omission of PMSF from the breaking buffer.

Expression of GATE-16 in Chinese Hamster Ovary (CHO) Cells-- The pcDNA3GATE-16-HA plasmid was transfected into CHO cells via electroporation (Bio-Rad kit) using 40 µg of DNA per 5 × 106 cells, according to the manufacturer's protocol.

Isolation of Cytosol from CHO Cells-- Cells were washed twice with phosphate-buffered saline, then twice in a homogenization buffer containing 0.25 M sucrose, 25 mM Tris-HCl, pH 7.4, and 50 mM KCl. The cells were then homogenized in the same buffer containing 1 mM PMSF, 2 µg/ml leupeptin, 2 µg/ml aprotonin, and 2 µM pepstatin A using a Balch homogenizer in all experiments except the experiment described in the legend to Fig. 1 in which a Dounce homogenizer was used. The homogenates were centrifuged for 5 min at 2500 rpm, and the supernatant was further centrifuged for 30 min at 200,000 × g. The supernatant containing the cytosol was collected.

Isolation of Cytosol from Crude Rat Brains-- Brains were homogenized in a breaking buffer (1 M KCl, 250 mM sucrose, 25 mM Tris, pH 7.4, 2 mM EGTA (in 100 mM Tris 7.4), 0.5 mM 1,10-phenanthroline, 1 mM DTT, 10 µg/ml aprotinin, 0.5 µg/ml leupeptin, 2 µM pepstatin A, and 1 mM PMSF) with a Dounce homogenizer using a B handle. The homogenate was then centrifuged in a Sorvall SS-34 rotor at 8500 rpm for 1 h and subsequently cleared by 1.5-h centrifugation at 35,000 rpm in a Beckman Ti60 rotor. The supernatant was dialyzed for 3 × 2 h against 5 liters (total) of dialysis buffer (50 mM KCl, 25 mM Tris, pH 7.4, and 10 mM beta -mercaptoethanol), cleared again at 35,000 rpm for 1.5 h, and stored at -70 °C until use.

Mass Spectrometry-- Protein samples were prepared from pure untagged recombinant GATE-16 (9) by incubation with HsApg4A in the presence of 1 mM DTT for 1 h. Mass spectra were acquired on API Q-STAR Pulsari electrospray-quadrupole time-of-flight mass spectrometer (MDS-Sciex and Applied Biosystems, Toronto, Canada) equipped with nano-electrospray ion source for sample introduction.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

GATE-16 Undergoes COOH-terminal Cleavage in Vivo-- GATE-16, a ubiquitin-like protein, was implicated in intra-Golgi transport and post-mitotic Golgi re-assembly. GATE-16 cDNA encodes for a 117-amino acid-long protein that is terminated by a VAYSGENTFGF sequence. Amino acid sequencing of five different tryptic peptides, obtained from endogenous GATE-16 isolated from bovine brain, revealed that all but one were terminated by lysine or arginine residues. The peptide corresponding to the COOH terminus of the protein, however, was found to be VAYSGENTFG (7). This finding alluded to the possibility that cytosolic GATE-16 lacks its last amino acid as a result of a specific protease activity. Consistently, it has been recently reported that Apg4p, a novel cytosolic cysteine protease, specifically removes a single amino acid from the COOH terminus of Aut7p, the yeast homologue of GATE-16 (19).

To investigate whether GATE-16 undergoes COOH-terminal cleavage by as yet an unknown protease, we expressed GATE-16 with a HA epitope attached to its carboxyl terminus (GATE-16-HA) in CHO cells. Cells were harvested after 48 h, and the cytosols were analyzed by Western blot using anti-HA and anti-GATE-16 polyclonal antibodies. In addition, two mutants in which glycine 116 or phenylalanine 115 were replaced with alanine (G116A-HA and F115A-HA, respectively) were used to determine whether these residues were essential for cleavage of the COOH terminus. The cleavage of the HA tag from GATE-16-HA is displayed in Fig. 1. Notably, the mutant G116A-HA remained intact, while F115A-HA was processed as the wild type protein, indicating that the highly conserved glycine 116, but not phenylalanine 115, is essential for the cleavage of GATE-16.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 1.   GATE-16 undergoes COOH-terminal cleavage in vivo. CHO cells were transfected with the mammalian expression vector pcDNA3 containing GATE-16 (WT) with an HA tag at its COOH terminus or mutants in which glycine 116 or phenylalanine 115 of GATE-16 were replaced with alanine (G116A and F115A, respectively). Cells were harvested 48 h after transfection, and their cytosols (40 µg per lane) were analyzed by Western blot using anti-HA and anti-GATE-16 antibodies as indicated. The primary antibodies were reacted either by peroxidase-conjugated anti-mouse or anti-rabbit, followed by enhanced chemiluminescence detection.

Characterization of the Cleavage Process-- A cell-free cleavage assay was used to further characterize this COOH-terminal processing. For that purpose, we produced recombinant GATE-16, tagged with six histidine residues (His6), at the NH2 terminus and HA at the COOH terminus. Similarly, a mutant protein, in which glycine 116 was replaced by alanine, was produced. These proteins were incubated at 30 °C with crude cytosols prepared from CHO cells or rat brains for different durations of up to 1 h and subsequently analyzed by Western blot, using anti-His monoclonal or anti-HA polyclonal antibodies (Fig. 2). Incubation of recombinant GATE-16-HA with CHO cytosol (or crude rat brain cytosol, data not shown) for a period of 20-30 min (Fig. 2B) resulted in removal of the HA tag. The use of anti-His6 antibodies (Fig. 2A, lower panel) revealed that the protein was cleaved to a shorter form and not degraded. In the control study, GATE-16-HA remained intact after incubation for 1 h in the reaction buffer (25 mM Tris, pH = 7.4, 50 mM KCl, and 10 mM beta -mercaptoethanol) at 30 °C, in the absence of crude cytosol, or in the presence of cytosol treated with the thiol alkylating agent NEM (see below). These results demonstrate that after incubation with cytosol, part of the COOH terminus of GATE-16 is cleaved. In accord with the results shown in Fig. 1, we found that the conserved glycine 116 is essential for this cleavage process.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 2.   Characterization of the cleavage process in a cell-free system. GATE-16 (WT) and the mutant G116A were cloned into pQE-30 vectors and expressed in E. coli to produce recombinant proteins tagged with His6 at the NH2 terminus and HA at the COOH terminus. Recombinant His6-GATE-16-HA (1 µg) was incubated at 30 °C with CHO cytosol (10 µg) in a reaction buffer that contained 25 mM Tris, pH 7.4, 50 mM KCl, and 10 mM beta -mercaptoethanol, under different conditions, and subjected to immunoblotting with anti-HA polyclonal antibodies, unless otherwise indicated. A, GATE-16 undergoes COOH-terminal cleavage by CHO cytosol. His6-GATE-16-HA WT (lanes 2 and 3) or G116A (lanes 4 and 5) were incubated with CHO cytosol for 1 h, in the presence (lanes 3 and 5) or in the absence (lanes 2 and 4) of 1 mM NEM. As a control, His6-GATE-16-HA was incubated in a reaction buffer without cytosol (lane 1). B, time course of the cleavage reaction. His6-GATE-16-HA was incubated with CHO cytosol for the indicated periods of time. As a control, incubation was carried out for 1 h in the presence of 1 mM NEM. C, the effect of protease inhibitors on the cleavage. His6-GATE-16-HA was incubated with CHO cytosol in the absence (lane 1) or in the presence of the following reagents: 1 mM NEM (lane 2), 1 mM PMSF (lane 3), 1 mM pepstatin A (lane 4), 10 mM 1,10-phenanthroline (lane 5), 10 mM EGTA (lane 6), and 10 mM BAPTA (lane 7).

We next tested the effect of different protease inhibitors on the cleavage. As shown in Fig. 2C, the process was strongly inhibited by two factors: NEM, a thiol alkylating agent known to inhibit cysteine proteases (lane 2), and PMSF, a serine-protease inhibitor (lane 3). Addition of pepstatine A, an aspartate-protease inhibitor (lane 4), or 1,10-phenanthroline, a metallo-protease inhibitor (lane 5), did not affect the cleavage. Neither was the process affected by Ca2+ chelating agents (EGTA and BAPTA, lanes 6 and 7, respectively). By contrast, addition of the reducing agent DTT significantly increased the level of cleavage (data not shown). These results could suggest that GATE-16 is processed by a partially similar mechanism to that of Aut7p.

Identification of the Mammalian Homologue of Apg4/Aut2-- The yeast Apg4p was recently suggested to have two putative homologues in humans (Fig. 3A) (19). We cloned HsApg4A and expressed it in E. coli, tagged with His6 at the NH2 terminus. Following purification on a Ni2+-NTA-agarose columns, we detected His6-HsApg4A as a major polypeptide of about 50 kDa (Fig. 3B).


View larger version (65K):
[in this window]
[in a new window]
 
Fig. 3.   Identification of the human Apg4A as a protease of GATE-16. A, alignment of the amino acid sequences of the two proposed HsApg4s (HsApg4A, NCBI accession number BAB83889, and HsApg4B, NCBI accession number BAB83890) with the yeast pApg4/pAut2 (accession number NP_014176). The alignment was preformed using the ClustalW multiple alignment program and is depicted by the ESPript 2.0 program, representing identity by a black frame and homology by a gray background. B, recombinant HsApg4A is detected as a polypeptide of 50 kDa. The cDNA of HsApg4A was cloned into a pQE-30 vector and expressed in E. coli to create a His6-tagged recombinant protein. Total bacterial cell lysate (lane 1) was loaded on a Ni2+-NTA column and eluted by imidazole as explained under "Experimental Procedures." The eluted fraction (lane 2) was run on 12% SDS-polyacrylamide gel and visualized by Coomassie Brilliant Blue staining. C, HsApg4A cleaves GATE-16-HA in vitro. Left panel, recombinant His6-GATE-16-HA (1 µg) was incubated with recombinant His6-HsApg4A (1 µg, lanes 1 and 2) in a reaction buffer (see legend to Fig. 2), for 1 h, at 30 °C, in the presence (lane 2) or absence (lane 1) of 1 mM DTT. As a control, GATE-16 was incubated with crude rat brain cytosol (10 µg) in the presence (lane 4) or absence (lane 3) of 1 mM NEM, or with a reaction buffer only (lane 5), without cytosol or HsApg4A. Right panel, the mutant His6-GATE-16-HA-G116A (1 µg) was incubated with recombinant His6-HsApg4A (1 µg, lane 2), in the presence of 1 mM DTT (at the conditions mentioned above). As a control, the mutant was incubated with a reaction buffer only (lane 1). Proteins were subsequently run on 15% SDS-PAGE and visualized by Coomassie Brilliant Blue staining.

To test whether HsApg4A is involved in the cleavage of GATE-16, we incubated recombinant His6-GATE16-HA with recombinant His6-HsApg4A, in the presence (Fig. 3C, left panel, lane 2) or in the absence (lane 1) of 1 mM DTT (19). In the presence of DTT, GATE-16-HA was cleaved to a shorter form; no cleavage was observed in the absence of DTT. In addition, HsApg4A did not cleave the mutant form of GATE-16, G116A (Fig. 3C, right panel, lane 2). These results indicate that HsApg4A, in the presence of the reducing agent DTT, is sufficient to cleave GATE-16 and thus may function as the mammalian homologue of Apg4. To determine the exact cleavage site of HsApg4A, we utilized pure recombinant GATE-16 isolated from E. coli with no tags attached to its NH2 or COOH termini. Pure GATE-16 was incubated with HsApg4A for 1 h at 30 °C, and the reaction mixture was subjected to electrospray ionization mass spectrometry. While the uncleaved GATE-16 yielded a single signal at 13,665.85, incubation with HsApg4A produced an additional signal at position 13,518.89. These signals correspond to the predicted molecular masses of the full-length (13,666) and the processed (13,519) GATE-16, indicating that GATE-16 was cleaved by HsApg4A just after glycine 116.

To further characterize this enzymatic reaction, we incubated a constant amount of GATE-16-HA with increasing amounts of HsApg4A (Fig. 4A) or crude rat brain cytosol (Fig. 4B) for 1 h and then analyzed the proteins by SDS-PAGE. Efficient cleavage of 1 µg (62 pmol) GATE-16 required at least 0.5 µg (11 pmol) of HsApg4A. GATE-16 was not fully cleaved by HsApg4A, even when larger amounts of HsApg4A were tested (up to 5 µg, data not shown). Under the same conditions, cleavage of GATE-16 by cytosol required 10 µg of rat brain cytosol. These results suggest that either HsApg4 is an extremely abundant protein or more likely that an additional cytosolic factor(s) is involved in the cleavage process.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 4.   Comparison of the cleavage activity of Apg4A and crude cytosol. Recombinant His6-GATE-16-HA (1 µg) was incubated with increasing amounts of HsApg4A, 0.001-1 µg (A), or crude rat-brain cytosol, 0.1-10 µg (B), in a reaction buffer (see legend to Fig. 2) containing 1 mM DTT for 1 h at 30 °C. The proteins were subsequently run on 15% SDS-PAGE, stained by Coomassie Brilliant Blue, and quantified with a densitometer using the Bio-Rad multi-analyst program. The black line represents the uncleaved GATE-16-HA, whereas the gray line represents the cleaved form.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

GATE-16 has been recently implicated in fusion processes that take place in the Golgi apparatus (7, 8, 23). Although it lacks a significant amino acid sequence similarity to ubiquitin, GATE-16 was found to contain a single ubiquitin fold subdomain decorated by two helices at its NH2 terminus (9). Like ubiquitin, GATE-16 is synthesized as a precursor protein. GATE-16 has a single, COOH-terminal phenylalanine residue following the conserved phenylalanine and glycine residues, and it stands to reason that this terminal phenylalanine residue must be removed for a conjugation process to take place. Here we showed that HsApg4A, a specific cysteine protease, cleaves GATE-16 at its COOH terminus. We presented evidence that this cleavage takes place in vivo and in vitro using either crude cytosol or purified HsApg4A. Our results indicate that HsApg4A specifically removes a single amino acid from the COOH terminus of GATE-16, thus exposing glycine 116. Furthermore, glycine 116 appears essential for this process inasmuch as replacing it with alanine abolishes the ability of GATE-16 to be cleaved. It appears that GATE-16 is a substrate for HsApg4A, which in turn renders it into a potential substrate for a ubiquitin-like conjugase. In accord with this suggestion, GATE-16, as well as its two other mammalian homologues, GABARAP and LC-3, were recently shown to be covalently attached to human homologues of E1 (Apg7)- and E2 (Apg3)-conjugating enzymes (Refs. 21 and 22, respectively).

HsApg4A exhibits significant amino acid sequence homology to the yeast autophagic factor Apg4p, a novel cysteine protease that specifically cleaves the carboxyl terminus of Aut7p downstream of Gly-116 (19). Apg4p has been shown to cleave the newly synthesized Aut7p, a reaction that precedes a ubiquitination-like process, mediated by E1 and E2 ligases, which specifically conjugates Aut7p to PE (20). Apg4p then releases Aut7p to the cytosol by cleaving the Aut7p-PE bond. These cleavage processes mediated by Apg4p are essential for both autophagy and cytosol to vacuole (Cvt) pathways (19). Interestingly, while in S. cerevisiae there is only a single Aut7p-like protein and a single Apg4p enzyme, mammals possess at least 10 different GATE-16-like proteins and at least 2 Apg4-like proteases. A possible explanation for this phenomenon is that HsApg4A cleaves the newly synthesized GATE-16 as well as the other members of the family, while its other mammalian homologue, HsApg4B, cleaves these proteins from their targets (possibly PE). Alternatively, it is feasible that different mammalian Apg4 proteins are specific to different subsets of the GATE-16 family members. This may imply that the two Apg4s have a different tissue specificity or subcellular localization or that they may be expressed at different developmental stages. Indeed, it has been recently reported that loss of one of the Apg4 homologues in Drosophila melanogaster resulted in significant defects in cut and Notch signaling pathways (24).

HsApg4a activity is similar to that of the deubiquitination enzymes and of SUMO-specific proteases. On the basis of their amino acid sequence homology, deubiquitinating enzymes can be broadly divided into two classes: the ubiquitin-processing protease (UBP) family and the ubiquitin carboxyl-terminal hydrolase (UCH) family (25-27). Both UBPs and UCHs are cysteine proteases containing in their active site cysteine, aspartate, and histidine residues. While UCH amino acid sequences are well conserved, UBPs share very limited homology (28). Recently, a distinct family of cysteine proteases acting on SUMO-1-conjugated substrates has been identified (28). The Apg4 family may be considered as a novel subgroup of these cysteine proteases that specifically cleaves the glycine-X bond at the COOH termini of different GATE-16-like family members. Little is known about the precise cellular function of UBPs and UCHs and the cellular mechanism that regulates their activity. Here we showed that the cleavage activity of recombinant HsApg4a is significantly lower than that found in crude cytosol, suggesting that other cellular factors are involved in the cleavage process. For example, HsApg4B may be required for reconstitution of the full cleavage activity implying that the two mammalian Apg4s act as a complex. Alternatively, the activity of Apg4A may be regulated by other yet unidentified protein(s). Such regulation of Apg4A activity may influence the function and possibly the subcellular localization of GATE-16 and its other family members.

GATE-16 is the closest mammalian homologue of Aut7. We have previously shown that Aut7p, similarly to GATE-16, interacts genetically and physically with several v-SNAREs, which are involved in ER to Golgi trafficking, and in vacuolar inheritance (29). GATE-16 has been found to act at late stages of membrane fusion, coincidentally with the Golgi SNARE GOS-28 (7, 8). The precise mechanism by which GATE-16 promotes fusion is yet unclear. It has been shown that GATE-16 binds preferentially to unpaired GOS-28 and inhibits GOS-28 binding to its cognate t-SNARE syntaxin 5 (8). This activity of GATE-16 is similar to the inhibition of syntaxin/VAMP binding by Munc18 (30) and the Sed5p/Bet1p binding by Sly1p (31). In the case of GATE-16, it may act as a SNARE protector that needs to be removed from GOS-28 prior to fusion (2). However, GATE-16 may actively promote fusion. Accordingly, the interaction with GOS-28 specifically localizes GATE-16 in a close proximity to the sites of fusion. Hence, the potential of GATE-16 to be transiently lipidated, similarly to its yeast homologue Aut7p (20), may serve to stimulate the formation a fusion pore during SNAREpin formation and bilayer mixing. The activity of HsApg4a described in the present work would be essential for such a process to occur.

    ACKNOWLEDGEMENTS

We thank Dr. Alla Shainskaya and Tevie Mehlman from the mass spectrometry laboratory at the Weizmann Institute of Science.

    FOOTNOTES

* This work was supported in part by the Israel Science Foundation and by the Weizmann Institute Minerva Center.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Incumbent of the Sholimo and Michla Tomarin Career Development Chair of Membrane Physiology. To whom correspondence should be addressed: Dept. of Biological Chemistry, The Weizmann Inst. of Science, Rehovot 76100, Israel. Tel.: 972-8-9343682; Fax: 972-8-9344112; E-mail: bmzevi@wicc.weizmann.ac.il.

Published, JBC Papers in Press, December 7, 2002, DOI 10.1074/jbc.M212108200

    ABBREVIATIONS

The abbreviations used are: SNARE, SNAP receptors; SNAP, soluble NSF attachment protein; NSF, NEM-sensitive factor; NEM, N-ethylmaleimide; v-SNARE, vesicle SNARE; t-SNARE, target membrane SNARE; GATE-16, Golgi-associated ATPase enhancer of 16 kDa; GABARAP, GABA receptor-associated protein; CHO, Chinese hamster ovary; E1, ubiquitin-activating enzyme; E2, ubiquitin carrier protein; PMSF, phenylmethylsulfonyl fluoride; Ni2+-NTA, nickel-nitrilotriacetic acid; DTT, dithiothreitol; BAPTA, 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid; UBP, ubiquitin-processing protease; UCH, ubiquitin carboxyl-terminal hydrolase.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Söllner, T., Whiteheart, S. W., Brunner, M., Erdjument, B. H., Geromanos, S., Tempst, P., and Rothman, J. E. (1993) Nature 362, 318-324[CrossRef][Medline] [Order article via Infotrieve]
2. Pfeffer, S. R. (1999) Nat. Cell Biol. 1, E17-E22[CrossRef][Medline] [Order article via Infotrieve]
3. McNew, J. A., Parlati, F., Fukuda, R., Johnston, R. J., Paz, K., Paumet, F., Sollner, T. H., and Rothman, J. E. (2000) Nature 407, 153-159[CrossRef][Medline] [Order article via Infotrieve]
4. Söllner, T., Bennett, M. K., Whiteheart, S. W., Scheller, R. H., and Rothman, J. E. (1993) Cell 75, 409-418[Medline] [Order article via Infotrieve]
5. Whiteheart, S. W., Rossnagel, K., Buhrow, S. A., Brunner, M., Jaenicke, R., and Rothman, J. E. (1994) J. Cell Biol. 126, 945-954[Abstract]
6. Mayer, A., Wickner, W., and Haas, A. (1996) Cell 85, 83-94[Medline] [Order article via Infotrieve]
7. Sagiv, Y., Legesse-Miller, A., Porat, A., and Elazar, Z. (2000) EMBO J. 19, 1494-1504[Abstract/Free Full Text]
8. Muller, J. M., Shorter, J., Newman, R., Deinhardt, K., Sagiv, Y., Elazar, Z., Warren, G., and Shima, D. T. (2002) J. Cell Biol. 157, 1161-1173[Abstract/Free Full Text]
9. Paz, Y., Elazar, Z., and Fass, D. (2000) J. Biol. Chem. 275, 25445-25450[Abstract/Free Full Text]
10. Mann, S. S., and Hammarback, J. A. (1994) J. Biol. Chem. 269, 11492-11497[Abstract/Free Full Text]
11. Kabeya, Y., Mizushima, N., Ueno, T., Yamamoto, A., Kirisako, T., Noda, T., Kominami, E., Ohsumi, Y., and Yoshimori, T. (2000) EMBO J. 19, 5720-5728[Abstract/Free Full Text]
12. Mizushima, N., Yamamoto, A., Hatano, M., Kobayashi, Y., Kabeya, Y., Suzuki, K., Tokuhisa, T., Ohsumi, Y., and Yoshimori, T. (2001) J. Cell Biol. 152, 657-668[Abstract/Free Full Text]
13. Wang, H., Bedford, F. K., Brandon, N. J., Moss, S. J., and Olsen, R. W. (1999) Nature 397, 69-72[CrossRef][Medline] [Order article via Infotrieve]
14. Kittler, J. T., Rostaing, P., Schiavo, G., Fritschy, J. M., Olsen, R., Triller, A., and Moss, S. J. (2001) Mol. Cell. Neurosci. 18, 13-25[CrossRef][Medline] [Order article via Infotrieve]
15. Kneussel, M. (2002) Brain Res. Brain Res. Rev. 39, 74-83[Medline] [Order article via Infotrieve]
16. Lang, T., Schaeffeler, E., Bernreuther, D., Bredschneider, M., Wolf, D. H., and Thumm, M. (1998) EMBO J. 17, 3597-3607[Abstract/Free Full Text]
17. Kirisako, T., Baba, M., Ishihara, N., Miyazawa, K., Ohsumi, M., Yoshimori, T., Noda, T., and Ohsumi, Y. (1999) J. Cell Biol. 147, 435-446[Abstract/Free Full Text]
18. Abeliovich, H., Dunn, W. A., Jr., Kim, J., and Klionsky, D. J. (2000) J. Cell Biol. 151, 1025-1034[Abstract/Free Full Text]
19. Kirisako, T., Ichimura, Y., Okada, H., Kabeya, Y., Mizushima, N., Yoshimori, T., Ohsumi, M., Takao, T., Noda, T., and Ohsumi, Y. (2000) J. Cell Biol. 151, 263-276[Abstract/Free Full Text]
20. Ichimura, Y., Kirisako, T., Takao, T., Satomi, Y., Shimonishi, Y., Ishihara, N., Mizushima, N., Tanida, I., Kominami, E., Ohsumi, M., Noda, T., and Ohsumi, Y. (2000) Nature 408, 488-492[CrossRef][Medline] [Order article via Infotrieve]
21. Tanida, I., Tanida-Miyake, E., Ueno, T., and Kominami, E. (2001) J. Biol. Chem. 276, 1701-1706[Abstract/Free Full Text]
22. Tanida, I., Tanida-Miyake, E., Komatsu, M., Ueno, T., and Kominami, E. (2002) J. Biol. Chem. 277, 13739-13744[Abstract/Free Full Text]
23. Legesse-Miller, A., Sagiv, Y., Porat, A., and Elazar, Z. (1998) J. Biol. Chem. 273, 3105-3109[Abstract/Free Full Text]
24. Thumm, M., and Kadowaki, T. (2001) Mol. Genet. Genomics 266, 657-663[CrossRef][Medline] [Order article via Infotrieve]
25. Tobias, J. W., and Varshavsky, A. (1991) J. Biol. Chem. 266, 12021-12028[Abstract/Free Full Text]
26. Papa, F. R., and Hochstrasser, M. (1993) Nature 366, 313-319[CrossRef][Medline] [Order article via Infotrieve]
27. Baker, R. T., and Board, P. G. (1991) Nucleic Acids Res. 19, 1035-1040[Abstract]
28. Wilkinson, K. D. (1997) FASEB J. 11, 1245-1256[Abstract/Free Full Text]
29. Legesse-Miller, A., Sagiv, Y., Glozman, R., and Elazar, Z. (2000) J. Biol. Chem. 275, 32966-32973[Abstract/Free Full Text]
30. Pevsner, J., Hsu, S. C., Braun, J. E., Calakos, N., Ting, A. E., Bennett, M. K., and Scheller, R. H. (1994) Neuron 13, 353-361[Medline] [Order article via Infotrieve]
31. Lupashin, V. V., and Waters, M. G. (1997) Science 276, 1255-1258[Abstract/Free Full Text]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.